Stay updated on Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial
Sign up to get notified when there's something new on the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page.

Latest updates to the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page
- CheckyesterdayChange DetectedThe revision identifier in the footer changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe study record page now shows a 403 Forbidden message with a minimal header and a Home link, indicating restricted access rather than changes to the study details.SummaryDifference16%

- Check22 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing the previous v3.6.6. This indicates a site-wide update rather than a modification to the study content.SummaryDifference0.0%

- Check36 days agoChange DetectedRevision: v3.6.6 appears, replacing v3.6.5; this denotes a page version update rather than substantive content changes to the study details.SummaryDifference0.0%

- Check57 days agoChange DetectedThe study details page updated to revision v3.6.5. Sponsor attribution and some helper-link sections were removed, changing how the sponsor information and navigation are presented.SummaryDifference0.1%

- Check78 days agoChange DetectedNew sections More Information and Helpful Links Provided by Naurex, Inc, an affiliate of Allergan plc have been added, and the revision notice was updated from v3.6.3 to v3.6.4.SummaryDifference0.1%

Stay in the know with updates to Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page.